Effect of monthly high-dose vitamin D on bone density in community-dwelling older adults substudy of a randomized controlled trial.
J Intern Med. 2017 Nov;282(5):452-460. doi: 10.1111/joim.12651. Epub 2017 Jul 26.
Reid IR1,2, Horne AM1, Mihov B1, Gamble GD1, Al-Abuwsi F1, Singh M1, Taylor L1, Fenwick S1, Camargo CA3, Stewart AW4, Scragg R4.
1 Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
2 Department of Endocrinology, Auckland District Health Board, Auckland, New Zealand.
3 Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
4 School of Population Health, University of Auckland, Auckland, New Zealand.
- Fractures reduced by monthly 30,000 IU of Vitamin D, perhaps 100,000 IU would be better – July 2019
- Falls cut in half by 100,000 IU vitamin D monthly - RCT 2016
- Hip fractures reduced 30 percent with 800 IU of vitamin D – meta-analysis July 2012
- Vitamin D and fractures – 24 meta-analyses and counting – Dec 2014
- Overview Fractures and vitamin D
- Hip bone loss stopped with 1000 IU of vitamin D, while 400 IU similar to placebo – RCT April 2013
Severe vitamin D deficiency causes osteomalacia, yet trials of vitamin D supplementation in the community have not on average demonstrated benefit to bone mineral density (BMD) or fracture risk in adults.
To determine whether monthly high-dose vitamin D supplementation influences BMD in the general population and in those with low 25-hydroxyvitamin D levels.
Two-year substudy of a trial in older community-resident adults. A total of 452 participants were randomized to receive monthly doses of vitamin D3 100 000 IU, or placebo. The primary end-point was change in lumbar spine BMD. Exploratory analyses to identify thresholds of baseline 25-hydroxyvitamin D for vitamin D effects on BMD were prespecified.
Intention-to-treat analyses showed no significant treatment effect in the lumbar spine (between-groups difference 0.0071 g cm-2 , 95%CI: -0.0012, 0.0154) or total body but BMD loss at both hip sites was significantly attenuated by ~1/2% over 2 years. There was a significant interaction between baseline 25-hydroxyvitamin D and treatment effect (P = 0.04). With baseline 25-hydroxyvitamin D ≤ 30 nmol L-1 (n = 46), there were between-groups BMD changes at the spine and femoral sites of ~2%, significant in the spine and femoral neck, but there was no effect on total body BMD. When baseline 25-hydroxyvitamin D was >30 nmol L-1 , differences were ~1/2% and significant only at the total hip.
This substudy finds no clinically important benefit to BMD from untargeted vitamin D supplementation of older, community-dwelling adults. Exploratory analyses suggest meaningful benefit in those with baseline 25-hydroxyvitamin D ≤ 30 nmol L-1 . This represents a significant step towards a trial-based definition of vitamin D deficiency for bone health in older adults.
PMID: 28692172 DOI: 10.1111/joim.12651